Literature DB >> 16076373

Structural and biochemical properties of fibroblast growth factor 23.

Takeyoshi Yamashita1.   

Abstract

Fibroblast growth factor (FGF) 23 shares a fundamentally common structure with the members of the FGF family and has a unique sequence extension at the C-terminus. The molecular behavior of FGF23 as a systemic factor can be justified by the altered conformation of the beta-trefoil structure similar to that suspected in FGF19. On the other hand, the biological activity of FGF23 is quite distinct from those of other FGFs and requires the C-terminal unique extended structure. Two types of enzyme-linked immunosorbent assays (ELISA) have been developed to detect the intact mature form of FGF23 and its C-terminal portion. The former ELISA method enables the detection of rodent FGF23 and human FGF23. Studies on experimental animal models and laboratory examinations of physiologic and disordered conditions using these assays are contributing toward elucidating the physiology and pathophysiology of FGF23.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16076373     DOI: 10.1111/j.1744-9987.2005.00288.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  17 in total

Review 1.  [FGF23 and Klotho: the new cornerstones of phosphate/calcium metabolism].

Authors:  J Bacchetta; P Cochat; I B Salusky
Journal:  Arch Pediatr       Date:  2011-04-16       Impact factor: 1.180

Review 2.  Does FGF23 toxicity influence the outcome of chronic kidney disease?

Authors:  Mohammed Shawkat Razzaque
Journal:  Nephrol Dial Transplant       Date:  2008-11-07       Impact factor: 5.992

Review 3.  Can features of phosphate toxicity appear in normophosphatemia?

Authors:  Satoko Osuka; Mohammed S Razzaque
Journal:  J Bone Miner Metab       Date:  2012-01-05       Impact factor: 2.626

4.  Klotho and fibroblast growth factor 23 in cerebrospinal fluid in children.

Authors:  Svenja Kristin Kunert; Hans Hartmann; Dieter Haffner; Maren Leifheit-Nestler
Journal:  J Bone Miner Metab       Date:  2016-03-26       Impact factor: 2.626

5.  FGF23 analysis of a Chinese family with autosomal dominant hypophosphatemic rickets.

Authors:  Yue Sun; Ou Wang; Weibo Xia; Yan Jiang; Mei Li; Xiaoping Xing; Yingying Hu; Huaicheng Liu; Xunwu Meng; Xueying Zhou
Journal:  J Bone Miner Metab       Date:  2011-06-28       Impact factor: 2.626

6.  Cord Blood Ferritin and Fibroblast Growth Factor-23 Levels in Neonates.

Authors:  Farah N Ali; Jami Josefson; Armando J Mendez; Karen Mestan; Myles Wolf
Journal:  J Clin Endocrinol Metab       Date:  2016-02-09       Impact factor: 5.958

7.  Evaluation of a method for fibroblast growth factor-23: a novel biomarker of adverse outcomes in patients with renal disease.

Authors:  Sridevi Devaraj; Catherine Duncan-Staley; Ishwarlal Jialal
Journal:  Metab Syndr Relat Disord       Date:  2010-08-13       Impact factor: 1.894

Review 8.  Osteo-renal regulation of systemic phosphate metabolism.

Authors:  Mohammed Shawkat Razzaque
Journal:  IUBMB Life       Date:  2011-03-24       Impact factor: 3.885

9.  Key role of the kidney in the regulation of fibroblast growth factor 23.

Authors:  Maria L Mace; Eva Gravesen; Jacob Hofman-Bang; Klaus Olgaard; Ewa Lewin
Journal:  Kidney Int       Date:  2015-07-29       Impact factor: 10.612

Review 10.  Mineral metabolism and aging: the fibroblast growth factor 23 enigma.

Authors:  Beate Lanske; M Shawkat Razzaque
Journal:  Curr Opin Nephrol Hypertens       Date:  2007-07       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.